MediWound Ltd. announced on May 13, 2025, the publication of a peer-reviewed post hoc analysis in Wounds journal. The analysis, based on data from the Phase II ChronEx clinical trial, evaluated EscharEx's efficacy and safety compared to collagenase ointment (SANTYL) in patients with venous leg ulcers (VLUs).
Key findings from the analysis showed that EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue compared to SANTYL. The study compared outcomes in a subgroup of 46 patients treated with EscharEx to 8 patients treated with SANTYL.
This publication provides clinical evidence of EscharEx's distinct advantages over the current market leader in wound debridement. The superior enzymatic formulation of EscharEx, which targets a wider range of non-viable tissue, positions it favorably for future market access and commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.